|Bid||0.8495 x 1100|
|Ask||0.8498 x 1000|
|Day's range||0.8210 - 0.9256|
|52-week range||0.2750 - 14.6100|
|Beta (5Y monthly)||-1.68|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.25|
Evofem Biosciences, Inc., (Nasdaq: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and six-month periods ended June 30, 2022 and affirmed full-year 2022 guidance.
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors. The appointment of Ms. Yip as a director expands the Board from five to six independent directors.
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced that the last subject has completed her last visit in EVOGUARD, the Company's registrational Phase 3 trial evaluating the efficacy and safety of Phexxi® (lactic acid, citric acid, potassium bitartrate) for the prevention of chlamydia and gonorrhea infection in women. There are no prescription pharmaceuticals approved to prevent these sexually transmitted infections (STIs).